Akeso Inc has commenced enrollment in a pivotal phase III clinical trial evaluating cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. The COMPASSION-33 study, the third Phase III trial for cadonilimab in gastric cancer, aims to enhance patient outcomes by improving the radical resection rate, reducing recurrence and metastasis risks. This innovative approach broadens the clinical application of cadonilimab by targeting PD-1 and CTLA-4 checkpoints simultaneously, potentially benefiting a larger population of gastric cancer patients. Cadonilimab, already approved in China for first-line treatment of advanced gastric cancer, has shown efficacy across various levels of PD-L1 expression and is being evaluated in combination with pulocimab for immune therapy-resistant cases.
With no approved perioperative immunotherapy regimens available globally, there is a significant unmet need in this area. Initial data on cadonilimab suggest superior efficacy and a more favorable safety profile compared to existing PD-1 therapies for perioperative treatment of G/GEJ adenocarcinoma. As the world’s first commercially available PD-1/CTLA-4 bispecific antibody, cadonilimab has demonstrated promising results in a phase III trial for advanced G/GEJ adenocarcinoma. Its ability to improve survival outcomes, especially in patients with low or negative PD-L1 expression, sets it apart from current PD-1 treatments, which have limited benefits in such populations. Akeso, founded in 2012, has established an integrated R&D platform focusing on innovative drug development, with over 50 assets in development, including bispecific antibodies and ADCs.
The strategic enrollment of the first patient in the phase III trial signifies a significant milestone for Akeso and the potential advancement of cadonilimab in the gastric cancer treatment landscape. By combining cadonilimab with chemotherapy, the study aims to not only increase the radical resection rate but also reduce recurrence and metastasis risks, ultimately enhancing patient outcomes. The innovative approach of targeting both PD-1 and CTLA-4 checkpoints simultaneously highlights the potential of cadonilimab to address critical unmet needs in gastric cancer treatment. Moreover, the ongoing evaluation of cadonilimab in combination with pulocimab for immune therapy-resistant cases underscores its versatility and potential to provide effective treatment options for challenging patient populations.
Akeso’s commitment to developing innovative solutions in oncology and other major disease areas is evident through its robust pipeline of over 50 assets, including bispecific antibodies and ADCs. The company’s integrated R&D platform and advanced drug development technologies position it as a key player in the biopharmaceutical industry. By leveraging global resources and prioritizing R&D innovation, Akeso aims to develop first-in-class and best-in-class therapies to meet the evolving needs of patients worldwide. The initiation of the phase III trial for cadonilimab reflects Akeso’s dedication to advancing novel treatment options and addressing unmet medical needs in gastric cancer and other disease areas.
- Akeso’s initiation of the phase III trial for cadonilimab in combination with chemotherapy for perioperative treatment of gastric cancer represents a significant milestone in addressing unmet medical needs in this challenging disease area.
- The innovative approach of simultaneously targeting PD-1 and CTLA-4 checkpoints with cadonilimab highlights its potential to improve patient outcomes and broaden its clinical application in gastric cancer treatment.
- Akeso’s integrated R&D platform and focus on developing novel therapies, including bispecific antibodies and ADCs, demonstrate its commitment to innovation and addressing critical unmet needs in oncology and other major disease areas.
- By leveraging global resources and strategic partnerships, Akeso aims to provide affordable and effective therapeutic solutions to patients worldwide, ultimately creating value both commercially and socially.
Tags: immunotherapy, regulatory, clinical trials
Read more on pharmabiz.com